Evaluation of Liver Enzymes Activities among Type 2 Diabetic Patients, Attending Alribat University Hospital, Khartoum State Evaluation of Liver Enzymes Activities among Type 2 Diabetic Patients

Main Article Content

Ayat Ali Eltayeb
Shereen Faisal
AbdElkarim A. Abdorabo
Suhair A.Ahmed
Rimaz Gurashi
GadAllah Modawe

Keywords

Liver enzymes,, Diabetes mellitus, , Sudanese patients, type2 DM

Abstract

Background: Diabetes mellitus is a metabolic disease known by chronic hyperglycemia which results from defective insulin action and secretion. Various studies have documented liver disease as a major cause of mortality in patients with type 2 diabetes. It is well known that the liver plays an important role in the maintenance of normal glucose levels during fasting as well as in the postprandial period Aim: To evaluate the levels of liver markers in type 2 diabetes patients in Khartoum state.  Materials and Methods: The study was conducted in Alribat University hospital, Sudan during the period from January 2018 to April 2019. Hundred subjects were included in the study, fifty patients previously diagnosed with Type 2 diabetes and similar number of age- andgender-matchedhealthy control subjects. The design of the study was cross-sectional, with a retrospective historical review through apersonal interview of all subjects.Blood was collected in a heparinized tube at room temperature and centrifuged for 10 minutes at 3500rpm, Serum liver markers concentrations were estimated by an enzymatic method in a fully Automated Biochemistry Analyzer (Cobas 3546). The data were analyzed using SPSS version 20.Results: The majority of patients were > 55 years. serum level of AST in type 2 diabetic patients and control group respectively were (31.26±10.34, 20.35±6.48) p value= 0.00), serum levels of ALT in type 2diabetic patients and control group respectively were (33.74±6.48, 19.70±6.23) p value= 0.00, serum level of ALP in Type 2 Diabetes patients and control group respectively were (125.20±49.61, 87.90±24.35) p value= 0.00,Serum level of GGT in Type 2 Diabetes patients and control group respectively were (47.72±9.01, 43.48±8.63) p value= 0.026. The mean BMI in type 2 diabetic patients and the control group respectively were (26.36±5.94,19.19±2.67), p value= 0.00, the correlation between duration of disease and liver enzymes GGT,ALT,AST and ALP respectively were (0.47,0.34,0.57,0.93). The current study showed in significant correlation between serum (GGT and ALT) and BMI of patients among type 2 diabetic patients (p value= 0.83,0.863) but significant correlation between serum (AST, ALT) and BMI of patients ( p value= 0.002,0.032).Conclusion: In the present study, a significant increase in the level of liver enzymes, ALT, AST, GGT ALP was observed in type 2 diabetic patients when compared to the normal group. Hence, we found an association between the level of liver enzymes, ALT, AST, and GGT in type 2 diabetic patients. Thus, these liver enzymes can be used as biomarkers for the assessment of type 2 diabetes, and we found no association between the level of liver enzymes, ALT, AST, and GGT in type 2 diabetic patients and duration of disease.

Abstract 57 | Full text PDF Downloads 28

References

1. IDF. International Diabetes Federation. IDF Diabetes Atlas—8th Edition. Diabetes Atlas. https://diabetesatlas.org/resources/2017-atlas.html. 2017. Accessed March 2019.
2. Kaneko K, Yatsuya1 H, Li Y, Uemura M, Chiang C, Hirakawa Y, et al. Association of gamma-glutamyltransferase and alanine aminotransferase with type 2 diabetes mellitus incidence in middle-aged Japanese men: 12-year follow up. J Diabetes Investig 2019;10:837–845.
3. Ichikawa K, Miyoshi T, Osawa K, Miki T, Toda H, Ejiri K, et al. Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: A prospective cohort study. Cardiovasc Diabetol [Internet]. 2021;20:8. https://doi.org/10.1186/s12933-020-01192-4.
4. Shibabaw T, Dessie G, Molla MD, Zerihun MF, Ayelign B. Assessment of liver marker enzymes and their association with type 2 diabetes mellitus in Northwest Ethiopia. BMC Res Notes [Internet]. 2019;12:707. https://doi.org/10.1186/s13104-019-4742-x
5. Islam S, Rahman S, Haque T, Sumon AH, Ahmed AZM, Ali N. Prevalence of elevated liver enzymes and its association with type 2 diabetes: A cross-sectional study in Bangladeshi adults. Endocrinol Diab Metab. 2020;3(2):e00116. https://doi.org/10.1002/edm2.116
6. Vilar-Gomez E, Calzadilla-Bertot L, Wong VWS, Castellanos M., Fuente RA, Eslam M, et al. Type 2 diabetes and metformin use associated with outcomes of patients with non-alcoholic steatohepatitis-related, Child-Pugh A Cirrhosis. Clin Gastroenterol and Hepatol [Internet]. 2020;19(1):136–145.e6. https://doi.org/10.1016/j.cgh.2020.04.083
7. Saligram S, Williams EJ, Masding MG. Raised liver enzymes in newly diagnosed Type 2 diabetes are associated with weight and lipids, but not glycaemic control. Indian J Endocrinol Metab [Internet]. 2012 Nov;16(6):1012–1014. doi: 10.4103/2230-8210.103027
8. Liu C, Shao M, Lu L, Zhao C, Qiu L, Liu Z. Obesity, insulin resistance and their interaction on liver enzymes. PLoS ONE [Internet]. 2021;16(4):e0249299. https://doi.org/10.1371/journal.pone.0249299
9. Li W, Homer K, Hull S, Boomla K, Robson J, Alazawi W. Obesity predicts liver function testing and abnormal liver results. Obesity (Silver Spring) [Internet]. 2019. pmid:31804018
10. Rogha M, Najafi N, Azari A, Kaji M, Pourmoghaddas Z, Rajabi F, et al. Non-alcoholic steatohepatitis in a sample of Iranian adult population: Age is a risk factor. Int J Prev Med. 2011;2(1):24.
11. Andersen T, Gluud C. Liver morphology in morbid obesity: A literature study. Int J Obes. 1984;8(2):97–106.
12. Kern W, Heger A, Payne J, DeWind L. Fatty metamorphosis of the liver in morbid obesity. Archives of Pathology. 1973;96(5):342–346.
13. Chandrashekhar, GS. Alterations of liver enzymes in T2DM: A case-control study. Int J Adv Med [Internet]. 2018;5(6). https://dx.doi.org/10.18203/2349-3933.ijam20184768
14. Wang Y-L, Koh W-P, Yuan J-M, Pan A. Association between liver enzymes and incident type 2 diabetes in Singapore Chinese men and women. BMJ Open Diabetes Res Care. 2016;4(1):e000296.
15. Chen SC-C, Tsai SP, Jhao J-Y, Jiang W-K, Tsao CK, Chang L-Y. Liver fat, hepatic enzymes, alkaline phosphatase and the risk of incident type 2 diabetes: A prospective study of 132,377 adults. Sci Rep. 2017;7(1):1–9.
16. Jha SK, Yadav NK, Rizal S. Prevalence of elevated liver enzymes and its association with type 2 diabetes: A descriptive cross-sectional study among Nepalese adults from Biratnagar, Nepal. Asian J Med Sci. 2021;12(6):50–55.
17. Islam S, Rahman S, Haque T, Sumon AH, Ahmed AM, Ali N. Prevalence of elevated liver enzymes and its association with type 2 diabetes: A cross‐sectional study in Bangladeshi adults. Endocrinol Diabetes Metab. 2020;3(2):e00116.
18. Palsamy P, Sivakumar S, Subramanian S. Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes’ ultrastructure in streptozotocin–nicotinamide-induced experimental diabetic rats. Chem Biol Interact. 2010;186(2):200–210.
19. Lucchesi AN, Cassettari LL, Spadella CT. Alloxan-induced diabetes causes morphological and ultrastructural changes in rat liver that resemble the natural history of chronic fatty liver disease in humans. J Diabetes Res. 2015;2015.
20. Welt K, Weiss J, Martin R, Dettmer D, Hermsdorf T, Asayama K, et al. Ultrastructural, immunohistochemical and biochemical investigations of the rat liver exposed to experimental diabetes und acute hypoxia with and without application of Ginkgo extract. Exp and Toxicol Pathol. 2004;55(5):331–345.
21. Sakharkar P, Deb S. Examining Liver function in adults with diabetes in the United States. J Pharm Sci. 2021;24:317–28.
22. Conen D, Vollenweider P, Rousson V, Marques-Vidal P, Paccaud F, Waeber G, et al. Use of a Mendelian randomization approach to assess the causal relation of γ-glutamyltransferase with blood pressure and serum insulin levels. Am J Epidemiol. 2010;172(12):1431–1441.
23. Conen D, Vollenweider P, Rousson V, Marques-Vidal P, Paccaud F, Waeber G, et al. Use of a Mendelian randomization approach to assess the causal relation of γ-glutamyltransferase with blood pressure and serum insulin levels. Am J Epidemiol. 2010;172(12):1431–1441.
24. Finelli C, Tarantino G. What is the role of adiponectin in obesity-related non-alcoholic fatty liver disease? World J Gastroenterol: WJG. 2013;19(6):802.
25. Balkau B, Lange C, Fumeron F, Bonnet F. Nine-year incident diabetes is predicted by fatty liver indices: The French DESIR study. BMC Gastroenterol. 2010;10(1):1–9.
26. Karp DR, Shimooku K, Lipsky PE. Expression of γ-glutamyl transpeptidase protects ramos B cells from oxidation-induced cell death. J Biol Chem. 2001;276(6):3798–3804.
27. Ceriello A. Oxidative stress and glycemic regulation. Metabolism. 2000;49(2):27–29.
28. Tarantino G, Caputi A. JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease. World J Gastroenterol: WJG. 2011;17(33):3785.
29. Mathur S, Mehta DK, Kapoor S, Yadav S. Liver function in type-2 diabetes mellitus patients. Int J Sci Study. 2016;3(10):43–47.
30. Forlani G, Di Bonito P, Mannucci E, Capaldo B, Genovese S, Orrasch M, et al. Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. J Endocrinol Investig. 2008;31(2):146–152.
31. Belkacemi L, Belalia M. Cross-sectional pilot study about the liver enzymes profile in type 2 diabetic patients from an Algerian west region: Wilaya of Mostaganem. Diabetes Metab Syndr. 2016;10(1):S147–S50.
32. Thambiah S, Ramley NS, Ghazali NS, Chuan NO, Nureslyna I, Samsudin SYZS. Deranged liver enzymes in type 2 diabetes mellitus subjects in a tertiary Malaysian hospital. Mal J Med Health Sci. 2019;15(2):62–68.
33. Judi L, Toukan A, Khader Y, Ajlouni K, Khatib MA. Prevalence of elevated hepatic transaminases among Jordanian patients with type 2 diabetes mellitus. Ann Saudi Med. 2010;30(1):25–32.
34. Mandal A, Bhattarai B, Kafle P, Khalid M, Jonnadula SK, Lamicchane J, et al. Elevated liver enzymes in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. Cureus. 2018;10(11).

Most read articles by the same author(s)